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Introduction
The plasma membrane of the cell is organized into cell surface 
domains that include clathrin-coated pits, lipid rafts, and caveo-
lae. Lipid rafts have been proposed to be transient and dynamic 
nanodomains of <10 nm in size (Mayor and Rao, 2004; for 
review see Hancock, 2006). Caveolae are invaginated lipid raft 
macrodomains (50–150 nm) whose stability at the plasma mem-
brane is attributable, in large part, to the formation of highly 
stable oligomers of their coat protein, caveolin-1 (Thomsen et al., 
2002; van Deurs et al., 2003; Parton et al., 2006). Clathrin-coated 
pits (100–150 nm) internalize rapidly upon formation at the same 
plasma membrane site, and their lateral cell surface mobility 
is enhanced by actin cytoskeleton depolymerization (Gaidarov 
et al., 1999). The membrane skeleton, which is associated with 
the cytoplasmic face of the plasma membrane, is composed of 
a meshwork of actin fi  laments and associated proteins that form 
fences and pickets that restrict molecular diffusion and parti-
tion the membrane into compartments that vary in size from 50 
to several hundred nanometers in size. Large-scale movements 
require the traversing of these compartmental boundaries via a 
process called hop diffusion, providing an explanation for the 
reduced diffusion of macromolecular complexes in biological 
membranes (Heuser and Kirschner, 1980; Edidin et al., 1991; 
Jacobson et al., 1995; Kusumi et al., 2005b; Morone et al., 
2006). However, the identifi  cation of physiological processes 
regulated by plasma membrane domain compartmentalization 
remains limited.
Molecular cross-linking of raft components has been 
proposed to generate stabilized domains that promote trans-
membrane signaling and interaction with the cytoskeleton 
(Simons and Toomre, 2000; Kusumi et al., 2004). Clustering of 
the glycosyl-phosphatidylinositol–anchored receptor CD59 was 
recently shown to result in the transient recruitment of Gαi2 
and Lyn and immobilization through binding to F-actin, which 
was termed stimulation-induced temporary arrest of lateral dif-
fusion (STALL); the recruitment of PLCγ to CD59 clusters 
undergoing STALL results in local IP3-Ca
2+ signaling events 
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acromolecular complexes exhibit reduced dif-
fusion in biological membranes; however, the 
physiological consequences of this characteristic 
of plasma membrane domain organization remain elusive. 
We report that competition between the galectin lattice and 
oligomerized caveolin-1 microdomains for epidermal growth 
factor (EGF) receptor (EGFR) recruitment regulates EGFR 
signaling in tumor cells. In mammary tumor cells deﬁ  -
cient for Golgi β1,6N-acetylglucosaminyltransferase V 
(Mgat5), a reduction in EGFR binding to the galectin lat-
tice allows an increased association with stable caveolin-1 
cell surface microdomains that suppresses EGFR signaling. 
Depletion of caveolin-1 enhances EGFR diffusion, respon-
siveness to EGF, and relieves Mgat5 deﬁ  ciency–imposed 
restrictions on tumor cell growth. In Mgat5
+/+ tumor 
cells, EGFR association with the galectin lattice reduces 
ﬁ  rst-order EGFR diffusion rates and promotes receptor 
interaction with the actin cytoskeleton. Importantly, EGFR 
association with the lattice opposes sequestration by 
caveolin-1, overriding its negative regulation of EGFR 
diffusion and signaling. Therefore, caveolin-1 is a condi-
tional tumor suppressor whose loss is advantageous when 
β1,6GlcNAc-branched N-glycans are below a threshold 
for optimal galectin lattice formation.
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(Suzuki et al., 2007a,b). Single-particle tracking analysis has 
shown that movement of cell surface–bound murine polyoma-
like virus particles is actin restricted, cholesterol dependent, and 
not associated with caveolae or clathrin-coated pits (Ewers et al., 
2005). However, the transient anchorage of cross-linked glycosyl-
phosphatidylinositol–anchored proteins was found to be depen-
dent on caveolin in addition to cholesterol and Src family 
kinases (Chen et al., 2006). Ras clustering upon activation sup-
ports a role for macromolecular complex formation in signal 
transduction (Murakoshi et al., 2004; Plowman et al., 2005).
Glycan-based domains generated by galectin binding to 
cell surface glycoproteins have been proposed (Brewer et al., 
2002). The Mgat5 gene encodes β1,6N-acetylglucosaminyl-
transferase V (GlcNAc-TV), a Golgi-processing enzyme that 
modifi  es N-glycans, generating high affi  nity ligands for ga-
lectins (Demetriou et al., 2001). The galectins are a family of 
β-galactoside–binding proteins with affi   nities for N-glycans 
proportional to GlcNAc branching (Hirabayashi et al., 2002) that 
can cross-link glycoproteins to form molecular lattices (Ahmad 
et al., 2004). Close interactions of galectin-3 on the cell surface 
have recently been shown by fl  uorescence resonance energy 
transfer, demonstrating that galectin-3 can oligomerize to form 
a lattice (Nieminen et al., 2007). We have shown that binding 
of Mgat5-modifi  ed N-glycans on EGF and TGF-β receptors 
to galectin-3 opposes receptor loss to constitutive endocytosis 
and, thereby, sensitizes cells to cytokines. Blocking clathrin-
coated pit endocytosis with potassium depletion and lipid raft 
endocytosis with nystatin rescued cytokine EGF and TGF-β 
sensitivity in Mgat5
−/− tumor cells (Partridge et al., 2004). This 
suggested that galectin binding protects receptors from nega-
tive regulation through interaction with clathrin-coated pits and 
lipid rafts. Herein, we demonstrate that the reduction of EGF 
receptor (EGFR) lateral mobility by Mgat5-dependent galectin-
mediated cross-linking limits interaction of the receptor with 
stable inhibitory domains of oligomerized caveolin. Our data 
indicate that recruitment to positive regulatory Mgat5/galectin-
dependent macromolecular complexes limits the large-scale 
macrodiffusion of EGFR, effectively competing with receptor 
recruitment to other plasma membrane domains.
Mgat5 gene expression and its β1,6GlcNAc-branched 
N-glycan products increase with oncogenic transformation in 
human cancers of the breast and colon and contribute directly to 
tumor progression and metastasis in mice (Dennis et al., 2002). 
In transgenic mice expressing the polyoma middle T antigen 
(PyMT) transgene under the control of the mouse mammary 
tumor virus (MMTV) long terminal repeat, Mgat5
−/− mice show 
delayed tumor development and considerably fewer lung me-
tastases compared with their Mgat5
+/+ littermates (Granovsky 
et al., 2000). In contrast to the Mgat5
−/− background, MMTV-
PyMT mammary tumorigenesis is accelerated in Cav1
−/− mice 
(Capozza et al., 2003; Williams et al., 2003).
Cav1 has been shown to act as a negative regulator of 
growth signaling (Razani et al., 2000; Parton and Simons, 2007) 
that, via its scaffolding domain (Okamoto et al., 1998; Smart 
et al., 1999), recruits EGF, PDGF, and TGF-β receptors to cave-
olae and suppresses responsiveness to these cytokines (Razani 
et al., 2001; Matveev and Smart, 2002; Di Guglielmo et al., 2003). 
The CAV1 gene maps to a tumor suppressor locus (D7S522; 
7q31.1) that is frequently deleted in human carcinomas, includ-
ing breast cancer (Williams and Lisanti, 2005). Up to 16% of 
human breast cancers express a CAV1 P132L mutation that cor-
relates with breast tumor progression and acts as a dominant 
negative for scaffold domain–dependent growth suppression 
(Hayashi et al., 2001; Lee et al., 2002). However, contrasting 
with its apparent tumor suppressor function, Cav1 expression 
is associated with a poor prognosis in multiple tumor types, in-
cluding breast tumors (Yang et al., 1999; Suzuoki et al., 2002; 
Savage et al., 2007).
The demonstration here that Mgat5 expression overrides 
the tumor suppressor function of Cav1 identifi  es the latter as a 
conditional tumor suppressor. The Mgat5-dependent galectin-
glycoprotein lattice is a positive signaling environment that reg-
ulates EGFR mobility and acts dominantly to protect receptors 
from negative regulation and immobilization through interaction 
with oligomerized Cav1. Mgat5-dependent expression of the 
galectin lattice relieves Cav1 suppression in Mgat5
+/+ PyMT 
mammary tumor cells, and responsiveness to EGF is rescued in 
Mgat5
−/− tumor cells by reducing Cav1 levels below a threshold. 
Our results demonstrate the competitive recruitment of EGFR 
to the extracellular galectin lattice and stable caveolin-1 micro-
domains and show that the integrity of these domains deter-
mines signaling potential and tumor progression.
Results
Reduced Cav1 expression is associated 
with increased EGFR signaling and tumor 
growth in Mgat5
−/− tumor cells
The majority of PyMT Mgat5
−/− tumors are small (<2 cm
3), 
but a minority (5–10%) of breast tumors in PyMT Mgat5
−/− 
mice display an acceleration of growth, suggesting escape from 
the suppressive effects of Mgat5 defi  ciency (Granovsky et al., 
2000). Mgat5
−/− and escaper Mgat5
−/−ESC tumor cell lines were 
established from small and large tumors, respectively, of MMTV-
PyMT Mgat5
−/− mice. Compared with Mgat5
+/+ mammary 
carcinoma cells, the Mgat5
−/− cell line is markedly less sensitive 
to EGF and TGF-β and is defi  cient in epithelial-mesenchymal 
transition (EMT) and fi  bronectin matrix deposition (Partridge 
et al., 2004; Lagana et al., 2006). In contrast to Mgat5
−/− cells, 
Mgat5
−/−ESC cells display levels of responsiveness to EGF 
that are comparable with that of wild-type Mgat5
+/+ cells 
(Fig. 1 A). However, responsiveness to TGF-β in both Mgat5
−/− 
and Mgat5
−/−ESC cells is impaired relative to Mgat5
+/+ cells 
(Fig. 1 B). Furthermore, both Mgat5
−/− and Mgat5
−/−ESC cells 
are defi  cient in EMT and fi  bronectin matrix deposition com-
pared with Mgat5
+/+ cells (Fig. 1 C). Therefore, the phenotypic 
rescue of Mgat5
−/−ESC cells, which is permissive for tumor 
growth in the absence of Mgat5, is associated with increased 
EGFR signaling but not TGF-β signaling, EMT, and fi  bronectin 
remodeling associated with Mgat5-dependent invasive tumor 
cell phenotypes.
Both Mgat5
−/− cell lines show the reduced expression of 
Cav1 relative to Mgat5
+/+ cells by both quantitative immuno-
fl  uorescence and Western blotting (Fig. 2, A and B). However, PLASMA MEMBRANE DOMAIN COMPETITION FOR EGFR • LAJOIE ET AL. 343
Cav1 and total Cav levels were reduced to a signifi  cantly greater 
extent (P < 0.05) in Mgat5
−/−ESC than in Mgat5
−/− cells (Fig. 2, 
A and B). Stable infection of Mgat5
−/− and Mgat5
−/−ESC cells 
with an Mgat5 expression vector generated rescued Mgat5
−/− 
(Rescue) and Mgat5
−/−ESC (ESC-Rescue) cell lines that present 
restored β1,6GlcNAc-branched N-glycan expression, as veri-
fi  ed by labeling with L-PHA–FITC that binds the β1-6 branch 
of N-glycans (Fig. 2 A). However, Cav1 expression was restored 
to wild-type levels only upon the rescue of Mgat5
−/− but not 
Mgat5
−/−ESC cells (Fig. 2, A and B). In Mgat5
+/+ cells, Cav1/2 
levels were reduced by swainsonine, an α-mannosidase II inhibitor 
that blocks N-glycan branching, and by β-lactose, a competi-
tive inhibitor of galectin binding at the cell surface (Fig. 2 B). 
Expression of Mgat5 and the N-glycan processing pathway can 
therefore impact Cav1. This suggests that Mgat5 and the ex-
pression of β1,6GlcNAc-branched N-glycans results in positive 
feedback to increase Cav1 levels. The failure of Mgat5 to restore 
Cav1 expression in Mgat5
−/−ESC cells suggests that additional 
genetic modifi  cations may occur in the larger escaper Mgat5
−/− 
tumors that block Cav1 up-regulation and suppression of growth.
Electron microscopic analysis of the cells shows a dramatic 
reduction in the number of cell surface–associated caveolae in 
both Mgat5
−/− and Mgat5
−/−ESC cells relative to Mgat5
+/+ or 
Rescue cells that express elevated Cav1 levels without affecting 
the number of clathrin-coated pits (Fig. 2 C). Cav1 is required 
for caveolae formation (Fra et al., 1995), suggesting that the 
threshold level of Cav1 required for caveolae formation is not 
attained in either Mgat5
−/− cell line. To probe for possible func-
tional interactions between Cav1 and the Mgat5-dependent 
lattice in tumor cells, we compared Cav1 protein levels and 
mammary tumor volume in MMTV-PyMT Mgat5
+/− and MMTV-
PyMT Mgat5
−/− mice at 12 wk of age. Cav1 levels in Mgat5
−/− 
tumor lysates correlated inversely with increased tumor growth, 
whereas no correlation with tumor size was observed in Mgat5
+/− 
tumors (Fig. 2 D). Therefore, reduced Cav1 is observed after 
either chemical disruption of the galectin lattice in Mgat5
+/+ 
mammary tumor cells in vitro and spontaneously with tumor 
progression in PyMT Mgat5
−/− tumors in vivo.
Cav1 regulates EGFR mobility and 
activation in the absence of the 
galectin lattice
To determine whether lower endogenous Cav1 levels in 
Mgat5
−/−ESC cells were permissive for cytokine responsive-
ness, Mgat5
−/−ESC cells were infected with an adenoviral vector 
for the expression of Cav1 (Fig. 3 A). Overexpression of Cav1 
protein levels in Mgat5
−/−ESC cells suppressed EGF-dependent 
Erk1/2 phosphorylation and nuclear translocation to levels 
Figure 1. Mgat5
−/−ESC cells show enhanced responsiveness to EGF. (A) Scan array determination of phospho-Erk nuclear translocation in Mgat5
+/+, 
Mgat5
−/−, and Mgat5
−/−ESC cells after stimulation with 100 ng/ml EGF for the indicated times of incubation. Representative phospho-Erk labeling of cells 
upon EGF stimulation for 5 min are shown. (B) Scan array determination of Smad nuclear translocation in Mgat5
+/+, Mgat5
−/−, and Mgat5
−/−ESC cells after 
stimulation with 100 ng/ml TGF-β for the indicated times of incubation. (C) In contrast to Mgat5
+/+ cells, Mgat5
−/− and Mgat5
−/−ESC tumor cells display 
E-cadherin–labeled (green) epithelial cell–cell adherens junctions (top) and little ﬁ  bronectin organized into ﬁ  brils (green). Cell nuclei are labeled with Hoechst (blue). 
Error bars represent SEM. Bars, 20 μm.JCB • VOLUME 179 • NUMBER 2 • 2007  344
comparable with untreated Mgat5
−/− cells (Fig. 3 A). Cav1 adeno-
viral infection of Mgat5
+/+ cells, Rescue, and ESC-Rescue 
cells did not inhibit EGF responsiveness (Fig. 3 A). This sug-
gests that the expression of β1,6GlcNAc-branched N-glycans 
protects EGFR from negative regulation by Cav1. This was 
confi  rmed by reducing Cav1 with siRNA in Mgat5
−/− cells 
that enhanced the EGF response, but this had no such effect in 
Mgat5
+/+, Mgat5
−/−ESC, or Rescue cell lines (Fig. 3 B). Thus, 
Mgat5 expression in tumor cells blocks the ability of Cav1 to 
act as a suppressor of EGFR signaling.
To explore the effects of Cav1 on cell surface raft dy-
namics, we measured the lateral diffusion rate of GM1-bound 
cholera toxin b subunit (CT-B) at the cell surface using FRAP 
at room temperature to limit the internalization of GM1-bound 
CT-B (Fig. 4 A and Table I; Nichols et al., 2001). Mgat5
−/−ESC 
cells exhibited increased CT-B diffusion relative to the other 
cell lines. Both the rate of diffusion and fractional recovery of 
CT-B into the FRAP region was increased in Mgat5
−/−ESC cells, 
suggesting that Cav1 contributes to the reduced mobility of 
CT-B. Indeed, surface diffusion of CT-B in Mgat5
−/−ESC cells was 
Figure 2.  Reduced Cav1 levels are associated with tumor growth in an Mgat5
−/− background. (A) Mgat5
+/+, Mgat5
−/−, Rescue, Mgat5
−/−ESC, and ESC-
Rescue cells were grown on coverslips for 48 h and stained with L-PHA–FITC (green; top) or Cav1 (green; bottom). Cell nuclei are stained with Hoechst 
(blue). Quantiﬁ  cation of L-PHA and Cav1 intensity is shown as a bar graph (n = 3; >25 cells per condition). (B) Equal protein amounts of cell lysates from 
Mgat5
+/+(2.6) and (2.8), Mgat5
−/− and Mgat5
−/−ESC, and Rescue and ESC-Rescue cells were Western blotted with Cav1/2 or Cav1-speciﬁ  c antibodies 
as indicated and quantiﬁ  ed by densitometry. Mgat5
+/+ were treated with 1 μM swainsonine (SW) or 20 mM β-lactose (β-lac) for 48 h, blotted for Cav1/2 
and β-actin, and quantiﬁ  ed by densitometry. (C) Representative electron micrographs of the plasma membrane of Mgat5
+/+, Mgat5
−/−, and Mgat5
−/−ESC 
cells. Quantiﬁ  cation revealed that both Mgat5-deﬁ  cient cell lines present reduced the expression of caveolae but not clathrin-coated pits. (D) Spontaneous 
MMTV-PyMT mammary carcinomas were dissected from 12-wk-old Mgat5
+/− and Mgat5
−/− mice and subjected to quantitative Western blotting of Cav1 
expression levels. Blots were also probed with γ-tubulin as a loading control, and levels of Cav1 were normalized to γ-tubulin levels as determined by den-
sitometry. Results are plotted against tumor volume. *, P < 0.05; **, P < 0.005 relative to Mgat5
+/+ unless otherwise indicated. Error bars represent SEM. 
Bars (A), 20 μm; (C) 0.2 μm. PLASMA MEMBRANE DOMAIN COMPETITION FOR EGFR • LAJOIE ET AL. 345
reduced upon transfection with Cav1–monomeric RFP (mRFP). 
Conversely, CT-B diffusion was enhanced by Cav1 siRNA 
treatment of Mgat5
+/+ and Mgat5
−/− cells and presented a profi  le 
equivalent to that of Mgat5
−/−ESC cells. Therefore, the increased 
Cav1 expression in Mgat5
−/− cells relative to Mgat5
−/−ESC cells 
correlates inversely with raft dynamics.
As observed for CT-B, EGFR-YFP showed enhanced cell 
surface diffusion and reduced immobile fraction in Mgat5
−/−ESC 
Figure 3.  Cav1 regulation of EGF signaling is selective for an Mgat5
−/− background. (A) Mgat5
+/+, Mgat5
−/−, Rescue, Mgat5
−/−ESC, and ESC-Rescue 
cells were infected with adenoviruses coding for myc-tagged Cav1 before stimulation with 100 ng/ml EGF for 5 min. Cells were ﬁ  xed and stained for 
phospho-Erk (green) and Cav1 (red), and nuclei were identiﬁ  ed by Hoechst staining (blue). Quantiﬁ  cation of untreated and EGF-treated cells presenting 
nuclear phospho-Erk is shown as a bar graph (n = 3; >36 cells per condition). (B) Mgat5
+/+, Rescue, Mgat5
−/−, and Mgat5
−/−ESC cells were treated 
with Cav1 siRNA, nonspeciﬁ  c (CTL) siRNA, or were left untreated (none) and blotted for Cav1 and γ-tubulin (γ-tub). Mgat5
+/+, Mgat5
−/−, Rescue, 
Mgat5
−/−ESC, and ESC-Rescue cells were transfected with nonspeciﬁ  c (CTL) siRNA or siRNA coding for Cav1 before stimulation with 100 ng/ml EGF 
for 5 min. Cells were ﬁ  xed and stained for phospho-Erk (green) and Cav1 (red), nuclei were identiﬁ  ed by Hoechst staining (blue), and representative 
confocal images of untreated and Cav1 siRNA–treated Mgat5
−/− cells are shown. The percentage of cells presenting nuclear phospho-Erk was 
quantiﬁ  ed in untreated and EGF-treated cells that were either untransfected (white bars) or transfected with Cav1 (black bars) or control (gray bars) 
siRNA and is shown as a bar graph (n = 3; >48 cells per condition). Error bars represent SEM. *, P < 0.01 relative to control untransfected cells. 
Bars, 20 μm. JCB • VOLUME 179 • NUMBER 2 • 2007  346
cells relative to Mgat5
−/− cells by FRAP analysis (Fig. 4 B and 
Table I). Cav1 transfection of Mgat5
−/−ESC cells reduced the 
diffusion rate and increased the immobile fraction, whereas 
Cav1 siRNA transfection of Mgat5
−/− cells had the oppos-
ing effect. In contrast, modulation of Cav1 levels in Mgat5
+/+ 
cells by either adenoviral Cav1 expression or Cav1 siRNA did 
not impact EGFR-YFP diffusion (Fig. 4 B and Table I). There-
fore, by limiting the exchange of EGFR-YFP between the 
bleached zone and the rest of the plasma membrane, Cav1 re-
stricts EGFR mobility, but only in the absence of the Mgat5/
galectin lattice.
In both Mgat5
+/+ and Mgat5
−/− cells, Cav1 migrates at 
the bottom of a 5–40% sucrose gradient (Monier et al., 1995; 
Sargiacomo et al., 1995), which is in contrast to monomeric 
RhoA that migrates in lower density fractions (Fig. 5 A). 
In blue native gels, Cav1 migrates at  500 kD in both cell lines 
(Fig. 5 B), corresponding to the high molecular mass oligomers 
of Cav1 reported previously (Monier et al., 1995; Sargiacomo 
et al., 1995). Therefore, in spite of the reduced expression of 
Cav1 and caveolae, Cav1 still forms stable oligomers in Mgat5
−/− 
cells. To compare the behavior of Cav1 at different expression 
levels, Mgat5
−/−ESC cells were transfected with Cav1-mRFP, 
Figure 4.  Cav1 regulation of plasma membrane diffusion of CT-B–FITC and EGFR-YFP. (A). Mgat5
+/+, Mgat5
−/−, and Mgat5
−/−ESC cells were incubated 
with 5 μg/ml FITC–CT-B at room temperature, and a portion of the cytoplasm was bleached and imaged for ﬂ  uorescent recovery. Percent intensity ± SEM 
(error bars) of FITC–CT-B in the bleached zone during recovery is shown for one representative experiment (n = 6 cells) for Mgat5
+/+ (left), Mgat5
−/− (middle), 
and Mgat5
−/−ESC (right) cells either untransfected (red) or transfected with Cav1 siRNA (blue) or Cav1-mRFP (+Cav1; black) as indicated. (B) Alternatively, 
Mgat5
+/+ (left), Mgat5
−/− (middle), and Mgat5
−/−ESC (right) cells transfected with EGFR-YFP (red) and subsequently transfected with Cav1 siRNA (blue) or 
infected with Cav1 adenovirus (+Cav1; black) were maintained at room temperature, and a portion of the cytoplasm was bleached and imaged for ﬂ  uor-
escent recovery. Percent intensity ± SEM of FITC–CT-B in the bleached zone during recovery is shown for one representative experiment (n = 6 cells). See 
Table I for quantitative values for all conditions tested. (C) Representative images of an EGR-YFP–transfected cell are shown prebleach, immediately after 
bleaching (T = 0), and after recovery (240 s). Bar, 20 μM.PLASMA MEMBRANE DOMAIN COMPETITION FOR EGFR • LAJOIE ET AL. 347
and the   diffusion of Cav1 was tested by FRAP (Fig. 5 C). 
The transfected cells were subsequently fi  xed and labeled for 
Cav1 to compare transfected Cav1-RFP expression levels with 
endogenous Cav1 levels in Mgat5
−/− and Mgat5
+/+ cells. Even 
when expressed at low levels, below those of Mgat5
+/+ cells, 
Cav1 remained highly immobile. Interestingly, the Cav1 mobile 
fraction but not the t1/2 of recovery increased significantly 
(P < 0.01) with Cav1 intensity. These results indicate that even 
when expressed at low levels, Cav1 still forms stable oligomers 
at the plasma membrane.
Mgat5
−/−ESC cells were transfected with mutants of Cav1, 
either a Y14F mutation of the tyrosine phosphorylation site or 
an F92A/V94A mutation of the scaffolding domain (Li et al., 
1996; Nystrom et al., 1999). Cav1-dependent inhibition of cell 
Table I. Percent mobile fraction and t1/2 of recovery for CT-B–FITC and EGFR-YFP as determined by FRAP
Cell transfection and/or 
treatment
Mgat5
+/+ Mgat5
−/− Rescue Mgat5
−/−ESC ESC-Rescue
Mf 
t1/2
Mf 
t1/2
Mf 
t1/2
Mf 
t1/2
Mf 
t1/2
% 
s
% 
s
% 
s
% 
s
% 
s
EGFR-YFP
 Control 64.8 ± 5.2 
33.9 ± 1.9
60.8 ± 5.9 
42.0 ± 3.3
68.6 ± 4.1 
34.6 ± 4.6
83.2 ± 3.0
a 
21.0 ± 4.1
a
68.3 ± 4.3 
35.5 ± 3.7
  +Cav1 adeno 57.2 ± 4.3 
34.3 ± 3.2
63.5 ± 4.7 
46.5 ± 3.7
63.5 ± 5.2 
32.5 ± 4.0
51.1 ± 2.8
b 
37.2 ± 4.2
b
66.5 ± 5.1 
35.7 ± 4.1
  + Cav1 wt 56.5 ± 4.9
b 
35.6 ± 4.7
b
  +Cav1 Y14F 53.6 ± 3.6
b 
36.5 ± 5.1
b
  +Cav1 F92A/V94A 78.7 ± 4.2 
24.6 ± 3.8
  +Cav1 siRNA 71.9 ± 5.0 
33.6 ± 5.6
91.0 ± 2.6
a,b 
29.7 ± 4.1
b
64.8 ± 4.8 
36.5 ± 5.1
80.1 ± 4.1
a 
23.3 ± 3.6
a
63.6 ± 4.8 
36.4 ± 5.0
  +Ctl siRNA 63.3 ± 4.2 
33.1 ± 2.1
59.3 ± 5.7 
42.2 ± 3.2
65.1 ± 4.2 
34.5 ± 4.1
85.4 ± 2.7
a 
22.4 ± 3.1
a
65.8 ± 4.6 
35.5 ± 4.1
  +Lactose 82.1 ± 4.7
b 
21.2 ± 2.2
b
57.6 ± 4.7
a 
46.2 ± 4.4
a
78.6 ± 3.6
b 
24.4 ± 4.3
b
79.2 ± 5.1 
22.9 ± 2.7
76.7 ± 4.1
b 
24.5 ± 4.0
b
  +Sucrose 60.2 ± 7.1 
36.5 ± 3.4
61.6 ± 4.4 
42.6 ± 4.0
66.3 ± 4.4 
32.5 ± 4.2
85.2 ± 4.6
a 
21.7 ± 4.7
a
65.3 ± 5.1 
37.2 ± 4.8
  +Lactose 
  +Cav1
67.3 ± 4.0
e 
19.7 ± 1.3
b
%
min
% 
min
% 
min
%
min
%
min
CT-B–FITC
 Control 26.9 ± 5.6 
1.7 ± 0.1
22.6 ± 5.2 
1.8 ± 0.2
23.5 ± 4.2 
1.7 ± 0.1
65.8 ± 4.8
a 
1.3 ± 0.2
c
62.2 ± 5.1
a 
1.2 ± 0.3
c
  +Cav1-RFP 24.5 ± 5.6 
1.8 ± 0.3
24.3 ± 3.1 
1.6 ± 0.2
24.5 ± 5.0 
1.8 ± 0.2
31.8 ± 6.1
b 
1.7 ± 0.1
d
26.9 ± 5.6
b 
1.8 ± 0.2
d
  + Cav1 WT 36.2 ± 5.0
b 
1.7 ± 0.2
d
  +Cav1 Y14F 34.3 ± 5.3
b 
1.8 ± 0.2
d
  +Cav1 F92A/V94A 58.2 ± 3.7 
1.3 ± 0.2
  +Cav1 siRNA 60.0 ± 5.4
b 
1.1 ± 0.2
d
71.9 ± 5.7
b 
1.2 ± 0.2
d
66.8 ± 5.2
b 
1.1 ± 0.2
d
61.5 ± 3.7 
1.2 ± 0.2
64.7 ± 4.1 
1.3 ± 0.2
  +Ctl siRNA 28.8 ± 5.2 
1.8 ± 0.2
22.4 ± 5.1 
1.9 ± 0.3
21.9 ± 4.3 
1.7 ± 0.1
62.4 ± 4.2
a 
1.3 ± 0.1
c
66.3 ± 3.7
a 
1.2 ± 0.2
c
  +Lactose 23.3 ± 4.2 
1.8 ± 0.3
23.4± 4.2 
1.9 ± 0.2
22.6 ± 4.1 
1.9 ± 0.3
66.9 ± 5.1
a 
1.2 ± 0.3
c
62.4 ± 4.3
a 
1.2 ± 0.3
c
  +Sucrose 24.0 ± 4.8 
1.6 ± 0.2
23.4 ± 4.6 
1.8 ± 0.3
22.4 ± 5.1 
1.8 ± 0.2
62.7 ± 3.9
a 
1.2 ± 0.2
c
64.0 ± 4.9
a 
1.2 ± 0.3
c
Mf, mobile fraction. Data are presented as means ± SEM.
aP < 0.01 compared with Mgat5
+/+(2.6).
bP < 0.01 compared with control.
cP < 0.05 compared with Mgat5
+/+(2.6).
dP < 0.05 compared with control.
eP < 0.01 compared with Mgat5
+/+(2.6) treated with lactose.JCB • VOLUME 179 • NUMBER 2 • 2007  348
Figure 5.  Cav1 regulation of EGFR signaling and cell surface diffusion requires an intact scaffolding domain but not Y14 phosphorylation. (A) N-octylglucoside 
lysates of Mgat5
+/+ and Mgat5
−/− cells were analyzed by velocity sucrose gradient centrifugation, and fractions were immunoblotted for Cav1 and mono-
meric RhoA as indicated. Fraction 1 is the top of the gradient, and fraction 12 is the bottom. (B) N-octylglucoside lysates of Mgat5
+/+ and Mgat5
−/− cells 
were separated on blue native gels and blotted for Cav1. (C) Mgat5
−/−ESC cells were transfected with Cav1-mRFP, and Cav1 diffusion was assessed by 
FRAP. Cav1 intensity in the bleached zone was determined by comparison of Cav1 labeling intensity with RFP ﬂ  uorescence in ﬁ  xed cells and was normal-
ized to Cav1 intensity in Mgat5
+/+ cells. Representative confocal images of high and low Cav1-mRFP–expressing cells are presented. Red boxed areas are 
enlarged in the insets to show details of Cav1 distribution. Mobile fraction (top graph) and half-time of recovery (bottom graph) in the function of Cav1 ex-
pression are presented. Linear regressions of the data points are shown as red lines. (D) Mgat5
−/−ESC cells were co-transfected with myc-tagged Cav1 wild 
type, Y14F mutant, or F92A/V94A scaffolding domain mutant as well as pOCT-dsRed to identify transfected cells and were incubated with CT-B–FITC at PLASMA MEMBRANE DOMAIN COMPETITION FOR EGFR • LAJOIE ET AL. 349
surface diffusion of both CT-B and EGFR-YFP (Fig. 5 D and 
Table I) and of EGFR signaling (Fig. 5 E) in Mgat5
−/−ESC cells 
is independent of Y14F phosphorylation but requires an intact 
scaffolding domain. Colocalization of EGFR and Cav1 is simi-
larly increased in Mgat5
−/−ESC cells transfected with wild-type 
Cav1 and Cav1-Y14F, but the Cav1 scaffolding domain mutant 
shows reduced colocalization with EGFR (Fig. 5 F).
Recruitment to the galectin lattice 
and EGFR diffusion
The mobile EGFR-YFP fraction was signifi  cantly greater (P < 
0.01) and the rate of recovery was signifi  cantly faster (P < 0.01) 
after photobleaching in Mgat5
+/+ cells treated with lactose than 
in untreated or sucrose-treated cells and was comparable with 
that observed in Mgat5
−/−ESC cells (Fig. 6 A and Table I). Lac-
tose treatment of Mgat5
+/+ also reduces Cav1 levels (Fig. 2 B). 
To determine whether reduced Cav1 levels are responsible for 
increased EGFR-YFP mobility, Cav1-transfected Mgat5
+/+ 
cells were treated with lactose. Cav1 overexpression increased 
the recruitment of EGFR to the immobile fraction but did not 
affect the fi  rst-order diffusion rate of EGFR compared with 
cells treated with lactose alone (Fig. 6 A and Table I). Disrupt-
ing the lattice with lactose did not alter CT-B diffusion in 
Mgat5
+/+ cells, suggesting that GM1 is not restricted by galec-
tins (Table I). Mgat5 retroviral rescue of Mgat5
−/− cells did not 
impact EGFR-YFP mobility, but the rescue of Mgat5
−/−ESC 
cells, which did not restore Cav1 levels, reduced the rate of 
recovery and the mobile fraction of EGFR-YFP (Fig. 6 A and 
Table I). This confi  rms that galectin binding to N-glycans re-
stricts the rate of diffusion of EGFR-YFP.
Colocalization of EGFR with Cav1 is increased in Mgat5
+/+ 
cells relative to Mgat5
−/− cells, and disruption of galectin bind-
ing in Mgat5
+/+ cells with lactose but not sucrose increases 
EGFR colocalization with Cav1 to levels observed in Mgat5
−/− 
cells (Fig. 6 B). To test Cav1 association with EGFR in live 
cells, Mgat5
−/−ESC and ESC-Rescue cells were cotransfected 
with Cav1-CFP and EGFR-YFP, and time-lapse videos were 
acquired every 10 s over 5 min. Cells were fi  xed and labeled 
for Cav1 to determine relative Cav1 levels, and the mean co-
localization of Cav1-CFP and EGFR-YFP was determined over 
the course of the video (Fig. 6 C and Videos 1–4; available 
at http://www.jcb.org/cgi/content/full/jcb.200611106/DC1). 
In ESC-Rescue cells, Cav1 association with EGFR was signif-
icantly lower (P < 0.01) than in Mgat5
−/−ESC cells, irrespective 
of Cav1 levels. These data are consistent with the competitive 
exchange of EGFR between two cell surface domains: a signaling-
competent Mgat5-dependent lattice and a negative regulatory 
Cav1-enriched microdomain.
The actin cytoskeleton restricts the 
mobility of EGFR-YFP in Mgat5
+/+ cells
To assess the role of the actin-based membrane skeleton on 
EGFR-YFP diffusion, the actin cytoskeleton was disrupted by 
treatment with latrunculin A (LatA). Phalloidin labeling of 
LatA-treated cells shows a loss of actin stress fi  bers and a 
reduction of total F-actin in Mgat5
+/+ and Mgat5
−/− cell lines 
(Fig. 7 A). Disruption of the actin cytoskeleton with LatA sig-
nifi  cantly increased (P < 0.05) the mobile fraction of EGFR-
YFP in Mgat5
+/+ cells (Fig. 7 B and Table II). The effect of 
LatA on EGFR stabilization in Mgat5
+/+ was also observed in 
Mgat5
+/+ cells overexpressing Cav1 or transfected with Cav1 
siRNA (Fig. 7 B and Table II). LatA treatment had no effect on 
either the rate of diffusion or the immobile fraction of EGFR in 
Mgat5
+/+ cells treated with lactose, or in either Mgat5
−/− cell 
line (Fig. 7 C). Therefore, lattice-associated EGFR shows pref-
erential interaction with the actin cytoskeleton relative to EGFR 
in the absence of the lattice. However, disruption of the actin 
cytoskeleton with LatA does not alter the fi  rst-order rate of 
EGFR diffusion. This suggests that the galectin lattice and 
F-actin act together to regulate the mobility of the non-Cav1–
associated fraction of EGFR.
Discussion
Competition between the galectin lattice 
and Cav1 domains regulates EGFR 
signaling
In this study, we show that negative regulation of EGFR through 
recruitment to Cav1 microdomains is opposed by the expression 
of β1,6GlcNAc-branched N-glycans. Therefore, Mgat5 and Cav1 
interact to regulate growth signaling and tumor progression. 
The galectin lattice impedes the diffusion rate of EGFR, con-
fi  rming our earlier report that the lattice represents a surface 
microdomain that limits EGFR down-regulation by endocytosis 
(Partridge et al., 2004). Lactose-mediated disruption of the 
galectin lattice in wild-type Mgat5
+/+ cells increases EGFR 
fi  rst-order diffusion, whereas restoration of the lattice by Mgat5 
expression in Mgat5
−/−ESC cells restricts EGFR diffusion in-
dependently of Cav1 expression. Cav1 overexpression reduces 
EGFR in the mobile fraction but does not suppress the effect of 
lactose on the fi  rst-order rate of diffusion of EGFR dynamics. 
The Cav1 microdomain and galectin lattice are therefore dis-
tinct cell surface domains that differentially regulate the distri-
bution and dynamics of EGFR.
Deletion of the EGFR cytoplasmic domain did not impact 
EGFR lateral mobility, leading to the suggestion that extra-
cellular interactions constrain the lateral diffusion of EGFR 
room temperature. Alternatively, myc-tagged Cav1 and mutants were cotransfected with EGFR-YFP. Percent intensity ± SEM (error bars) in the bleached 
zone for CT-B–FITC and EGFR-YFP during recovery is shown for one representative experiment (n = 6 cells). See Table I for quantitative values for all condi-
tions tested. (E) Mgat5
−/−ESC cells were transfected with myc-tagged Cav1 wild type (WT), Y14F mutant, or F92A/V94A scaffolding domain mutant. Cells 
stimulated with 100 ng/ml EGF for 5 min were ﬁ  xed and stained with anti–phospho-Erk and anti-myc to identify myc-tagged Cav1-labeled cells. Nuclei 
were identiﬁ  ed by Hoechst staining. Quantiﬁ  cation of phospho-Erk nuclear translocation from confocal images is shown as a bar graph (n = 3; >24 cells 
per condition). *, P < 0.05. (F) Mgat5
−/−ESC cells transfected with myc-tagged Cav1 wild type, Y14F mutant, or F92A/V94A scaffolding domain mutant 
were immunoﬂ  uorescently labeled with anti-EGFR (green) and anti-myc to localize myc-Cav1 (red) in the absence of ligand. Red boxed areas are enlarged 
in the insets to reveal the incidence of colocalization. The percentage of EGFR spots that overlap with Cav1 is presented in graphic form. *, P < 0.05. 
Bars, 20 μm.JCB • VOLUME 179 • NUMBER 2 • 2007  350
Figure 6.  The Mgat5/galectin lattice restricts EGFR diffusion and limits interaction with Cav1 domains. (A) Percent intensity ± SEM (error bars) in the 
bleached zone of EGFR-YFP during recovery is shown for one representative experiment (n = 6 cells) for Mgat5
+/+ cells (top) either untreated (Ctl) or treated 
with 20 mM lactose (+Lac) for 48 h or infected with Cav1 adenovirus and treated with 20 mM lactose for 48 h (+Lac+Cav1). Percent intensity ± SEM in 
the bleached zone of EGFR-YFP during recovery is shown for one representative experiment (n = 6 cells) for Mgat5
−/− and Rescue cells (top) and for 
Mgat5
−/−ESC and ESC-Rescue cells (bottom). See Table I for quantitative values for all conditions tested. (B) Mgat5
+/+ and Mgat5
−/− cells either untreated 
or pretreated for 48 h with 20 mM lactose or sucrose (not depicted) were immunoﬂ  uorescently labeled for EGFR (red) and Cav1 (green) in the absence 
of ligand. Higher magniﬁ  cation images are presented to reveal the incidence of colocalization. The percentage of EGFR spots that overlap with Cav1 is PLASMA MEMBRANE DOMAIN COMPETITION FOR EGFR • LAJOIE ET AL. 351
(Livneh et al., 1986). Mgat5 defi  ciency and lactose competition 
have previously been shown to inhibit galectin binding to EGFR 
(Partridge et al., 2004), identifying a requirement for extracellu-
lar galectin binding to N-glycans in the regulation of EGFR dif-
fusion at the cell surface. We envisage that recruitment to the 
galectin lattice reduces the propensity of EGFR to perform 
hop diffusion. Disruption of the actin cytoskeleton with LatA 
increased the mobile fraction but not the rate of diffusion of 
EGFR-YFP, distinguishing its action from lactose-mediated 
disruption of the lattice. Although we cannot exclude the possi-
bility of incomplete disruption of the submembrane actin cyto-
skeleton by LatA (Lagana et al., 2006), our data are consistent 
with a role for membrane protein density as a key regulator of 
diffusion rates in biological membranes (Fujiwara et al., 2002; 
Frick et al., 2007). Importantly, the effect of actin cytoskeleton 
disruption was not observed in Mgat5
−/− or Mgat5
+/+ cells 
treated with lactose where the galectin lattice is reduced. There-
fore, galectin-bound EGFR is also stabilized by the actin cyto-
skeleton. It is likely that galectin cross-links EGFR to other 
actin-associated membrane glycoproteins, generating actin-
stabilized signaling domains (Fig. 8).
It is important to note that the scale of measurement with 
respect to both time and domain size using FRAP is dramat-
ically larger than that measured by single-particle tracking 
(Kusumi et al., 2005a). Thus, it is not clear whether the Cav1- 
dependent immobilization of EGFR that we have measured 
by FRAP is equivalent to the cholesterol-dependent transient 
anchorage observed by single-particle tracking (Pralle et al., 2000; 
Dietrich et al., 2002; Ewers et al., 2005; Chen et al., 2006; Smith 
et al., 2006). The immobile fraction detected by FRAP in our 
study refl  ects those EGFR-YFP molecules whose interaction 
with other plasma membrane components, such as Cav1, the 
galectin lattice, or the actin cytoskeleton, constrains their ability 
to exchange freely with fl   uorescent EGFR-YFP outside the 
bleached region. This may not necessarily refl  ect stable or even 
direct molecular interactions but rather the preferential recruit-
ment of EGFR to microdomains that restrict protein exchange 
across membrane barriers (Fig. 8).
Figure 7.  The actin cytoskeleton restricts EGFR mobility. (A) Mgat5
+/+, Mgat5
−/−, and Mgat5
−/−ESC cells either untreated or treated with LatA for 20 min 
were ﬁ  xed and stained with phalloidin-AlexaFluor568 (red) and Hoechst (blue). (B) Percent intensity ± SEM (error bars) in the bleached zone of transfected 
EGFR-YFP during recovery is shown for one representative experiment (n = 6 cells) of untreated and LatA-treated Mgat5
+/+ cells (top) or for untreated and 
LatA-treated Mgat5
+/+ cells infected with Cav1 adenovirus (+Cav1) or transfected with Cav1 siRNA (+Cav1 siRNA; bottom). (C) Percent intensity ± SEM 
in the bleached zone of transfected EGFR-YFP during recovery is shown for one representative experiment (n = 6 cells) of Mgat5
+/+ cells pretreated for 48 h 
with 20 mM lactose with (+Lac+LatA) or without (+Lac) Lat A (top) as well as untreated and LatA-treated (+LatA) Mgat5
−/− and Mgat5
−/−ESC (ESC) cells 
(bottom). See Table II for quantitative values for all conditions tested. Bar, 20 μm.
presented in graphic form. *, P < 0.01 relative to untreated cells. (C) Time-lapse images of Mgat5
−/−ESC and ESC-Rescue cells cotransfected with Cav1-CFP 
and EGFR-YFP were acquired every 10 s for 5 min. Merged images of representative cells expressing high and low Cav1-CFP levels are displayed with 
equivalent Cav1 acquisition settings and enhanced Cav1 intensity. Images are shown for t = 0, and higher magniﬁ  cations of regions boxed in red are 
shown every minute for 5 min to reveal the incidence of colocalization. Cav1-CFP intensity was quantiﬁ  ed relative to Mgat5
+/+ cells (top graph), and mean 
Pearson’s colocalization coefﬁ  cients determined from the time-lapse videos are presented for high and low Cav1-expressing cells (bottom graph). See Videos 1–4 
(available at http://www.jcb.org/cgi/content/full/jcb.200611106/DC1). Error bars represent SEM. *, P < 0.01. Bars, 20 μm.JCB • VOLUME 179 • NUMBER 2 • 2007  352
Cav1 microdomains
Activation of EGFR has been shown to occur in noncaveo-
lar raft domains that associate with nascent coated pits (Puri 
et al., 2005). Similarly, in Mgat5
+/+ cells, blocking coated pit 
endocytosis by K
+ depletion leads to the precocious activa-
tion of Erk and growth signaling that can be suppressed by 
the disruption of rafts with nystatin (Partridge et al., 2004). 
Negative regulation of EGFR diffusion and signaling by Cav1 
oligomers is consistent with the previously reported stable in-
teraction of EGFR with Cav1 and caveolae (Couet et al., 1997; 
Mineo et al., 1999; Matveev and Smart, 2002). However, the 
ability of Cav1 to form immobile oligomers that associate with 
and regulate EGFR diffusion and signaling at levels below the 
threshold for caveolae formation argues that oligomerized Cav1 
can functionally sequester EGFR independently of caveolae 
formation. Indeed, in endothelial cells, the overexpression of 
Cav1 inhibits endothelial nitric oxide synthase activity without 
increasing caveolae expression, suggesting that a pool of Cav1 
outside of caveolae may be responsible (Bauer et al., 2005; 
Parton and Simons, 2007).
Freeze-etch experiments have identifi  ed a striated caveolin 
coat on fl  at membrane domains as well as caveolae   (Rothberg 
et al., 1992), and threshold levels of Cav1 in cell surface do-
mains are required for caveolae formation (Breuza et al., 2002). 
Furthermore, in contrast to the caveolae-rich basolateral surface of 
MDCK cells, the apical surface expresses Cav1 but no caveolae 
(Verkade et al., 2000). Caveolin forms stable oligomers (Monier 
et al., 1995; Sargiacomo et al., 1995), and the caveolin coat of 
vesicular transporters is highly stable (Pelkmans et al., 2004). 
Cav1 regulation of EGFR signaling and dynamics in Mgat5
−/− 
cells that express few caveolae suggests that the regulatory 
function of Cav1 is dependent on Cav1 oligomerization but not 
necessarily on caveolae formation.
Cav1 oligomers show a reduced mobility relative to larger 
(more intense) Cav1 structures (Fig. 5 C), perhaps refl  ecting in-
creased dynamics and exchange of Cav1 in caveolae. However, 
in the absence of Mgat5 expression, Cav1 at varying expression 
levels functions equivalently to regulate the diffusion of CT-B 
and EGFR as well as EGFR signaling. In blue native gel analy-
sis, Cav1 in Mgat5
−/− cells migrates as a sharp band, which is 
indicative of a highly stable oligomeric confi  guration. Similar 
SDS stable oligomers were predicted to contain 15 caveolin 
molecules (Monier et al., 1995). This is considerably less than 
the predicted 145 Cav1 molecules per caveolae (Parton et al., 
2006) and is consistent with the reduced intensity and size of 
the Cav1 spots detected in cells expressing reduced levels of 
Cav1, such as Mgat5
−/− cells. The stable interaction of EGFR 
with Cav1 oligomers argues that these domains form a stable 
platform for the recruitment of receptors and other interacting 
proteins. Although the spatial relationship of Cav1 oligomers, 
the galectin lattice, and the membrane skeleton remains uncer-
tain, we suggest that the reduced mobility of both Cav1 oligo-
mers and the galectin lattice is caused by the reduced ability of 
proteins and lipids recruited to these macromolecular domains 
to undergo hop diffusion (Fig. 8).
Cav1 is a conditional tumor suppressor
Spontaneous down-regulation of Cav1 in Mgat5
−/− tumor cells 
argues that these conditions select for relief from the Cav1-
mediated negative regulation of signaling at the cell surface. 
In Mgat5
+/+ cells, inhibition of the lattice with swainsonine or 
lactose treatment reduced Cav1 expression, whereas the Mgat5 
rescue of Mgat5
−/− cells restored Cav1 levels. This suggests 
that β1,6GlcNAc branching is an upstream regulator of Cav1. 
The inability of Mgat5 rescue to restore Cav1 levels in Mgat5
−/−ESC 
cells is suggestive of Cav1 loss caused by a stable genetic 
change. Moreover, the inverse correlation between Cav1 levels 
and tumor size in Mgat5
−/− tumors suggests that reducing Cav1 
expression is one mechanism that can relieve growth restriction 
imposed by Mgat5 defi  ciency.
PyMT Mgat5
−/− mice display a dramatic reduction in the 
incidence of tumor metastasis, even in those animals that de-
velop escaper fast growth tumors (Granovsky et al., 2000). 
In this regard, although responsiveness to EGF is largely restored 
Table II. Percent mobile fraction and t1/2 of recovery for EGFR-YFP after treatment with LatA as determined by FRAP
EGFR-YFP
−LatA +LatA
Mf t1/2 Mf t1/2
% min % min
Mgat5
+/+
 Control 65.3  ± 4.2 36.4 ± 3.7 77.4 ± 4.6
a 37.7 ± 4.2
  +Cav1 adeno 63.6 ± 5.1 34.4 ± 4.4 76.4 ± 3.2
a 41.5 ± 5.2
  +Cav1siRNA 66.2 ± 4.1 35.3 ± 4.2 74.5 ± 3.4
a 36.7 ± 4.6
  +Ctl siRNA 64.1 ± 4.2 34.5 ± 4.3 78.6 ± 3.8
a 39.6 ± 4.4
  +Lactose 80.3 ± 4.5 24.5 ± 3.1 77.4 ± 4.8 23.2 ± 3.5
  +Sucrose 63.1 ± 4.6 35.9 ± 3.4 75.0 ± 4.1
a 36.6 ± 3.0
Mgat5
−/−
 Control 62.4  ± 4.3 40.4 ± 4.5 64.5 ± 3.8 38.7 ± 3.8
Mgat5
−/−ESC
 Control 78.4  ± 5.3 22.6 ± 3.7 76.6 ± 4.9 24.5 ± 4.2
Mf, mobile fraction. Data are presented as means ± SEM.
aP < 0.05 compared with absence to LatA.PLASMA MEMBRANE DOMAIN COMPETITION FOR EGFR • LAJOIE ET AL. 353
by Cav1 suppression in Mgat5
−/−ESC cells, it does not rescue the 
lattice-dependent defi  ciency in TGF-β signaling, EMT, or fi  bro-
nectin fi  brillogenesis. This suggests that Mgat5 and β1,6GlcNAc-
branched N-glycans play additional roles that are distinct from 
Cav1 regulation in tumor cell polarity, motility, and invasion 
(Cheung and Dennis, 2007).
In contrast to Mgat5
−/− tumor cells, EGFR diffusion and 
responsiveness to EGF are not altered by either the overexpres-
sion or partial knockdown of Cav1 expression in Mgat5
+/+ cells. 
This suggests that β1,6GlcNAc-branched N- glycans and lattice 
retention of EGFR override negative regulation by Cav1. Although 
Mgat5-defi  cient tumor cells are partially depleted of surface 
EGFR as a result of constitutive endocytosis (Partridge et al., 
2004), reducing Cav1 levels in the cells appears to compensate 
by increasing the availability of EGFR to ligand-dependent 
activation. We conclude that unlike Mgat5
−/− cells, in which 
Cav1 expression is signifi  cantly higher (P < 0.05), Cav1 levels 
in Mgat5
−/−ESC cells are below the threshold required for sup-
pression, leaving an estimated 10–15,000 surface EGFRs avail-
able for optimal activation of the MAPK activation (Partridge 
et al., 2004; Lau et al., 2007). Surface residency of EGFR in the 
lattice is therefore permissive for ligand activation and limits 
both constitutive endocytosis (Partridge et al., 2004) and seques-
tration by inhibitory, immobile Cav1 domains (Fig. 8). Thus, 
Cav1 depletion enhances the availability of surface EGFR on 
Mgat5
−/− cells, thereby removing a negative regulator of growth 
(Fig. 8). We suggest that Cav1 loss compensates for an approxi-
mately fi  vefold decrease in surface EGFR numbers observed in 
Mgat5
−/− cells (Partridge et al., 2004) and is thus epistatic for 
EGF sensitivity.
There are only 400–800 TGF-β receptors per cell with a 
short surface t1/2 ( 2 h) compared with >10
5 surface EGFRs with 
a t1/2 > 6 h. TβRII has few N-glycans (n = 2) compared with 
EGFR (n = 8) and is therefore relatively more dependent on the 
branching of its N-glycans for residency in the lattice at the cell 
surface (Lau et al., 2007). In contrast, EGFR has both a greater 
 affi  nity for the lattice as a result of the higher N-glycan number 
and a greater sensitivity to regulation by Cav1 microdomains 
(Fig. 1). Therefore, our data argue that affi  nity for the galectin 
lattice and Cav1-enriched microdomains partners with receptor 
endocytosis rates to determine receptor availability to ligand.
Finally, elevated Mgat5 expression in advanced tumors 
may render the suppressor function of Cav1 redundant by main-
taining receptor tyrosine kinases in the galectin lattice within a 
physical spacing that precludes association with Cav1 micro-
domains. These results provide support for Cav1 as a condi-
tional tumor suppressor, whose loss is advantageous when 
β1,6GlcNAc-branched N-glycans are below a threshold for op-
timal lattice formation. Depletion of Cav1 or increased Mgat5 
expression both support early stage tumor growth; importantly, 
expression of the latter will permit the elevated Cav1 levels 
associated with poor prognosis in some tumor types.
Materials and methods
Mice and cell lines
Transgenic mice deﬁ  cient in Mgat5 expression were crossed onto PyMT 
transgenic mice on a 129sv × FVB background (Granovsky et al., 2000). 
Mammary tumor samples were dissected from Mgat5
+/− and Mgat5
−/− 
mice and snap frozen on dry ice for subsequent protein extraction. Cell 
lines were established from solid mammary carcinoma samples dissected 
from either Mgat5
+/+ or Mgat5
−/− genotypes. The cell lines used herein 
are designated Mgat5
+/+(2.6), Mgat5
+/+(2.8), Mgat5
−/− (also called 
Mgat5
−/−(22.9)), and Mgat5
−/−ESC (also called Mgat5
−/−(22.10)). 
Mgat5
−/− and Mgat5
−/−ESC cells genetically rescued by infection with a 
pMX-PIE retroviral vector for the expression of murine Mgat5 (designated 
Rescue and ESC-Rescue, respectively) were selected by growth in medium 
containing 1 μg/ml puromycin (Partridge et al., 2004). All cell lines were 
grown in complete medium containing DME supplemented with 10% FBS, 
nonessential amino acids, glutamine, vitamins, and penicillin/streptomycin 
in a 5% CO2/air incubator at 37°C. For signal transduction experiments, 
cells were rinsed twice and incubated overnight in serum-free DME at 37°C 
before performing the experiment. Disruption of the actin cytoskeleton was 
performed by treating cells with 0.5 μM LatA in complete DME for 20 min 
at 37°C before experiments.
Constructs, transfection, adenoviral infection, and siRNA
EGFR-YFP was obtained from Z. Wang (University of Alberta, Edmonton, 
Canada), pOCT-dsRED was obtained from H. McBride (University of Ottawa, 
Ottawa, Canada), and myc-tagged Cav1 wild type and the F92A/V94A 
Figure 8.  Domain competition between the 
galectin lattice and oligomerized Cav1 micro-
domains regulates EGFR signaling. In Mgat5-
expressing cells, EGFR is recruited to galectin 
lattice domains that limit EGFR diffusion, promote 
interaction with the actin-based membrane 
skeleton, and limit interaction with negative 
regulatory oligomerized Cav1 microdomains 
(A) such that the reduction of Cav1 expression 
impacts neither EGFR diffusion nor signaling 
(B). In the absence of the Mgat5/galectin lat-
tice, EGFR freely diffuses across membrane 
skeleton boundaries and is recruited to Cav1 
oligomers as well as caveolae that negatively 
regulate signaling (D), and Cav1 down-regula-
tion restores EGFR signaling (E). EGFR in the 
galectin lattice stably interacts with the  membrane 
skeleton (A and B), and depolymerization of 
the actin cytoskeleton increases EGFR exchange 
within the galectin lattice but does not enhance 
the rate of EGFR diffusion or interaction with 
Cav1 microdomains (C and F). The diagram was 
adapted from Morone et al. (2006).JCB • VOLUME 179 • NUMBER 2 • 2007  354
scaffolding domain mutant were obtained from M.J. Quon (National Insti-
tutes of Health, Bethesda, MD). Human Cav1 was inserted into pRFP-N1 
and tyrosine(Y)14 mutated to phenylalanine (F) by using the PCR-based 
overlapping extension technique (forward, 5′-GG  G  A  A  T  T  C  T  A  G  C  A  T  G  T  C  T-
G  G  G  G  G  C  A  A  A  T  A  C  G  T  A  G  A  C  T  C  G  G  A  G  G  G  A  C  A  T  C  T  C  T  T  C  A  C  C  -3′; reverse, 
5′-G  G  G  A  T  C  C  C  C  A  G  A  T  C  C  T  C  T  T  C  T  G  A  G  A  T  G  A  G  -3′). Cells were transfected 
using Effectene (QIAGEN) 24 h before experiments.
Adenovirus expressing myc-tagged Cav1 under control of the tetra-
cycline-regulated promoter was used to infect cells for 48 h as previously 
described (Zhang et al., 2000; Le et al., 2002). Infected cells were visual-
ized using anti-myc (Santa Cruz Biotechnology, Inc.) antibody. To knock 
down Cav1 expression, cells were cultured in complete medium for 2 d be-
fore transfection with speciﬁ  c mouse Cav1 siRNA oligonucleotides or with 
control siRNA (Dharmacon, Inc.). In brief, cells were rinsed twice with 
  serum-free DME without antibiotics, transfected with siRNA for 4 h using 
Dharmafect 3 transfection reagent (Dharmacon, Inc.), washed twice with 
complete DME, and incubated in complete media for 48 h.
Western blotting
Cells were lysed in TNTE (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1 mM EDTA, and protease inhibitor cocktail [Sigma-Aldrich]). 
Lysate protein levels were quantiﬁ  ed using BCA Protein Assay Reagents A 
and B (Pierce Chemical Co.). Western blots of 30 μg of total protein were 
probed with polyclonal antibodies against Cav1, Cav1/2 (Transduction 
Laboratories), γ-tubulin (clone GTU-88; Sigma-Aldrich), or β-actin (Sigma-
Aldrich) followed by the appropriate HRP-conjugated secondary antibodies 
and chemiluminescence. Band intensity was quantiﬁ   ed by densitometry 
with Image analysis software (Scion).
Blue native gels were performed as described previously (Ren et al., 
2004). In brief, cells were lysed at 4°C in lysis buffer (500 mM 6-amino 
caproic acid, 2 mM EDTA, and 25 mM Bistris, pH 7.0) containing 120 mM 
N-octyl-glucoside for 30 min. Lysates were clariﬁ  ed by centrifugation at 
13,200 rpm for 10 min. Supernatant were mixed with 1/10 vol of sample 
buffer containing 5% R-250 Coomassie blue and 1/10 vol glycerol. Pro-
teins were separated on linear 4–15% acrylamide gels run at 100 V 
at 4°C until the dye reached the middle of the gel. Blue cathode buffer 
(50 mM Tricine, 15 mM Bistris, and 0.02% R-250 Coomassie blue) was 
then replaced with clear cathode buffer (with no Coomassie blue), and gels 
were run at 200 V until the dye reached the bottom of the gels. Proteins 
were then transferred to polyvinylidene diﬂ   uoride membrane and pro-
cessed for immunoblotting with Cav1 polyclonal antibody (Santa Cruz Bio-
technology, Inc.).
Electron microscopy
Cells were rinsed with 0.1 mM sodium cacodylate, pH 7.3, ﬁ  xed for 1 h 
with 2% glutaraldehyde at 4°C, rinsed with cacodylate buffer, scraped 
from the Petri dish, pelleted, and postﬁ  xed with 2% osmium tetroxide at 
4°C. The cells were dehydrated and embedded in LR-White resin. Ultrathin 
sections were prepared, contrasted with uranyl acetate and lead citrate, 
and visualized with a CM902 or a H7600 transmission electron micro-
scope (Carl Zeiss MicroImaging, Inc. or Hitachi, respectively). Smooth 
caveolar invaginations and clathrin-coated vesicles within 100 nm of the 
plasma membrane were counted per cell proﬁ  le as previously described 
(Le et al., 2002).
Nuclear translocation of Erk and Smad2/3
Cells were plated in 96-well plates at 5,000 cells/well or on coverslips, 
serum starved for 24 h, and stimulated with EGF or TGF-β1 in DME plus 
0.2% FBS. After various times with cytokine, cells were ﬁ  xed for 10 min with 
3.7% formaldehyde at 20°C, washed with PBS plus 1% FBS, and permeabil-
ized using 100% MeOH for 2 min. The cells were washed three times and 
blocked in PBS plus 10% FBS for 1 h at 37°C. Mouse anti–phospho-Erk1/2 
(Thr202/Tyr204; Sigma-Aldrich) or mouse anti-Smad2/3 (Transduction 
Laboratories) was added at 1/1,000 in PBS plus 10% FBS and incubated 
overnight at 4°C. The cells were washed three times with PBS plus 1% FBS 
and AlexaFluor488-labeled anti–mouse Ig (Invitrogen) added at 1/1,000 
with Hoechst (1/2,000) for 1 h at 20°C. After washing three times, the 
plates were scanned using an ArrayScan automated ﬂ  uorescence micro-
scope (Cellomics Inc.). The difference in nuclear and cytoplasmic staining 
intensity was determined individually for 100 cells per well, and subtraction 
of total nuclear intensity values from cytoplasmic intensity values was used 
to represent the change in activation after the addition of cytokine. The SEM 
(n = 100) was generally <4% at each assay point.
Alternatively, cells were plated on coverslips for 24 h and trans-
fected with either myc-tagged Cav1, Cav1Y14F, or Cav1F92AV94A or 
with Cav1 siRNA or control siRNA for 2 d. Cells were serum starved for 24 h 
before stimulation with 100 ng/ml EGF for 5 min and were ﬁ  xed and 
labeled with mouse anti–phospho-Erk1/2 and either rabbit anti-myc (Santa 
Cruz Biotechnology, Inc.) or rabbit anti-Cav1 (Santa Cruz Biotechnology, 
Inc.) followed by Hoescht staining. Confocal images of cells mounted in 
Celvol 205 (Celanese Ltd.) were acquired on a confocal microscope 
(Fluoview 1000; Olympus) with a Uplan Apochromat 1.35 NA 60× ob-
jective (Olympus) with equivalent acquisition settings. The mean intensity of 
nuclear phospho-Erk was quantiﬁ  ed by creating a mask based on Hoescht 
staining using ImagePro Plus software (Media Cybernetics, Inc.). Data from 
three independent experiments (>36 cells/condition) were compiled and 
normalized to Mgat5
+/+ cells stimulated for 5 min with EGF.
FRAP
FRAP analysis of cells incubated with CT-B for 3 min or transfected with 
EGFR-YFP was performed in regular culture media without phenol red 
at room temperature. Images were acquired on a confocal microscope 
(FV1000; Olympus) with a Uplan Apochromat 1.35 NA 60× objective 
(Olympus) and fully opened pinhole. Photobleaching of CT-B–FITC was 
performed using 10 scans with the 488-nm laser at full power within a 
square area 20 pixels wide. EGFR-YFP photobleaching experiments were 
performed using 20 scans of a 405-nm scanner laser (SIM; Olympus) at 
full power within a circular region of interest of 27-pixel diameter. To study 
the effect of Cav1 on CT-B diffusion, cells were transfected with Cav1-mRFP, 
Cav1Y14F-mRFP, Cav1F92AV94A-mRFP, or Cav1 siRNA 2 d before exper-
iments. Disruption of the galectin lattice was performed by treating the 
cells with 20 mM β-lactose or sucrose for 2 d. To study EGFR diffusion, cells 
were plated for 6 h and transfected with EGFR-YFP. The next day, cells 
were transfected with Cav1 or control siRNA or infected with Cav1 adeno-
virus. After 4 h, the media was changed to complete DME or complete 
DME containing 20 mM β-lactose or sucrose for 2 d. Recovery data (six to 
eight cells from each of three independent experiments) were analyzed 
with Prism software (GraphPad) using nonlinear regression with a bottom 
to bottom + span algorithm. t1/2 of recovery and mobile fraction were cal-
culated as previously described (Reits and Neefjes, 2001). For experi-
ments using myc-tagged Cav1 constructs, cells were cotransfected with 
either EGFR-YFP or pOCT-dsRED to visualize the transfected cells. Similarly, 
recovery data for transfected Cav1-mRFP in Mgat5
−/−ESC cells were ob-
tained by FRAP analysis at room temperature. Images were acquired with 
equivalent acquisition settings, and, to compare Cav1-mRFP intensity with 
endogenous Cav1 levels, Mgat5
+/+-, Mgat5
−/−-, and Cav1-mRFP–trans-
fected Mgat5
−/−ESC cells were ﬁ   xed and labeled in parallel with Cav1 
polyclonal antibody (Santa Cruz Biotechnology, Inc.). A graph of Cav1 in-
tensity versus Cav1-mRFP intensity was generated for ﬁ  xed Mgat5
−/−ESC 
cells, and a linear regression was performed to determine the intensity of 
Cav1-mRFP relative to endogenous Cav1 levels in Mgat5
+/+ cells in the 
bleach zone of live cells that underwent FRAP analysis. FRAP data are pre-
sented in function of normalized Cav1-mRFP intensity for both the mobile 
fraction and half-time of recovery. r
2 values were calculated from a linear 
regression performed with Prism software (GraphPad).
Quantitative immunoﬂ  uorescence
L-PHA and Cav1 expression levels were quantiﬁ  ed from ﬂ  uorescent images of 
cells mounted in Celvol 205 (Celanese Ltd.) acquired with the 60× 1.35 NA 
Uplan Apochromat objective (Olympus) of a confocal microscope 
(Fluoview 1000; Olympus). Quantiﬁ  cation of L-PHA–FITC levels (mean den-
sity of ﬂ  uorescence) was performed using ImagePro Plus software (Media 
Cybernetics, Inc.) from confocal images acquired with equivalent acquisi-
tion settings. Values from three independent experiments were normalized 
to the intensity of Mgat5
+/+ cells, and signiﬁ  cance was determined by a 
t test. To measure EGFR colocalization with Cav1, cells were plated on glass 
coverslips and preincubated for 48 h with 20 mM β-lactose or sucrose in 
complete DME, ﬁ  xed, and labeled with rabbit anti-EGFR, mouse anti-Cav1 
(Invitrogen), and Hoechst. Images were acquired with a 100× NA 1.4 
Plan Apochromat objective (Olympus) of a microscope (DeltaVision Res-
toration; Olympus), and 64-layer stacks were acquired and deconvolved 
with softWoRx image analysis software (Applied Precision). Colocalization 
was quantiﬁ  ed in Photoshop (Adobe) by deﬁ  ning a box of set dimensions 
and scoring the incidence of yellow stain within this box from six randomly 
selected regions within the cytoplasm of the cell. Alternatively, cells trans-
fected with myc-tagged Cav1 constructs were labeled with anti-myc (Upstate 
Biotechnology) and anti-EGFR. From confocal images of cells mounted in 
Celvol 205 (Celanese Ltd.) acquired with the 60× 1.35 NA objective of a 
confocal microscope (FV1000; Olympus), the relative intensity of myc-Cav1 
associated with EGFR labeling was determined using the colocalization 
coefﬁ  cient of ImagePro Plus imaging software (Media Cybernetics, Inc.).PLASMA MEMBRANE DOMAIN COMPETITION FOR EGFR • LAJOIE ET AL. 355
To quantify EGFR-Cav1 association in live cells, Mgat5
−/−ESC and 
ESC-Rescue cells were cotransfected with Cav1-CFP and EGFR-YFP. Time-
lapse images of cells were acquired every 10 s for 5 min in regular culture 
media without phenol red at room temperature with the 60× 1.35 NA 
Uplan Apochromat objective of the FV1000 confocal microscope. Cav1 ac-
quisition settings were kept constant, and high and low Cav1-CFP–expressing 
cells were determined relative to endogenous Cav1 levels in Mgat5
+/+ 
cells. The Pearson’s coefﬁ  cient for Cav1-CFP and EGFR-YFP was calculated 
from two random regions of the cell for each individual time frame, and the 
mean Pearson’s coefﬁ  cient over time was determined from three indepen-
dent experiments (n >15) using ImagePro Plus software.
Cav1 oligomerization gradients
Cav1 oligomerization was determined using velocity sucrose gradient cen-
trifugation as previously described (Monier et al., 1996). In brief, cells 
were grown in 100-mm Petri dishes and lysed on ice in 500 μl of lysis 
buffer (25 mM MES, pH 6.5, 150 mM NaCl, 60 mM N-octylglucoside, 
and protease inhibitor cocktail). This lysate was overlaid on top of 4.2 ml 
of a 5–30% discontinous sucrose gradient prepared in the same lysis buffer. 
The gradients were centrifuged in an SW55 rotor (Beckman Coulter) for 6 h 
at 53,000 rpm. 12 equal fractions of 392 μl were collected from the top 
of the gradient, and an equal volume of each fraction was analyzed by 
SDS-PAGE and transferred onto nitrocellulose membranes for immuno-
blotting with anti-Cav1 (Santa Cruz Biotechnology, Inc.) or anti-RhoA (Santa 
Cruz Biotechnology, Inc.) antibodies.
Online supplemental material
Videos 1–4 correspond to Fig. 6 C. Mgat5
−/−ESC and ESC-Rescue cells 
were transfected with Cav1-CFP (red) and EGFR-YFP (green). Videos are 
of Mgat5
−/−ESC cells expressing high (Video 1) and low (Video 2) Cav1 
levels and ESC-Rescue cells expressing high (Video 3) and low (Video 4) 
Cav1 levels. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200611106/DC1.
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